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Systemic inflammation and duration of immobilization are strong independent risk factors 
for the development of intensive care unit-acquired weakness (ICUAW). Activation of the 
pro-inflammatory transcription factor nuclear factor-κB (NF-κB) results in muscle wasting 
during disuse-induced skeletal muscle atrophy (ICU bed rest) and septic shock. In addi-
tion, NF-κB-mediated signaling plays a significant role in mechanical ventilation-induced 
diaphragmatic atrophy and contractile dysfunction. Older trials investigating high dose 
glucocorticoid treatment reported a lack of a sustained anti-inflammatory effects and 
an association with ICUAW. However, prolonged low-to-moderate dose glucocorticoid 
treatment of sepsis and ARDS is associated with a reduction in NF-κB DNA-binding, 
decreased transcription of inflammatory cytokines, enhanced resolution of systemic 
and pulmonary inflammation, leading to fewer days of mechanical ventilation, and lower 
mortality. Importantly, meta-analyses of a large number of randomized controlled trials 
investigating low-to-moderate glucocorticoid treatment in severe sepsis and ARDS 
found no increase in ICUAW. Furthermore, while the ARDS network trial investigating 
methylprednisolone treatment in persistent ARDS is frequently cited to support an 
association with ICUAW, a reanalysis of the data showed a similar incidence with the 
control group. Our review concludes that in patients with sepsis and ARDS, any poten-
tial direct harmful neuromuscular effect of glucocorticoids appears outweighed by the 
overall clinical improvement and reduced duration of organ failure, in particular ventilator 
dependency and associated immobilization, which are key risk factors for ICUAW.
Keywords: acute respiratory distress syndrome, glucocorticoid treatment, intensive care unit-acquired weakness, 
mechanical ventilation, survival, steroids, muscle weakness
Intensive care unit (ICU)-acquired weakness (ICUAW) is a condition that can either affect the 
peripheral nerves [critical illness polyneuropathy (CIP)], the skeletal muscle [critical illness myo-
pathy (CIM)], or both and involves functional or structural changes in these tissues (1). Systemic 
inflammation (increased inflammatory cytokine levels) and associated organ dysfunction during 
early critical illness are strong independent risk factors for the development of CIM (2). As inflam-
matory infiltrates are rarely seen in muscle and nerve tissue in patients with ICUAW, the functional 
and structural damage may not be caused directly by inflammatory cell infiltration and activation, 
but rather stem from cytokine-driven electrophysiological alterations, endothelial and microvascular 
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alterations, metabolic changes, and bio-energetic failure, ulti-
mately leading to axonal cell death, pronounced muscle atrophy, 
and contractile dysfunction (3, 4).
In ARDS, inadequate GC-glucocorticoid receptor α (GRα)-
mediated downregulation of the pro-inflammatory transcription 
factor nuclear factor-κB (NF-κB) in circulating and tissue-
resident cells leads over time (>4 weeks) to a persistent elevation 
in plasma inflammatory cytokine levels indicating dysregulated 
systemic inflammation (5). NF-κB signaling is also involved in 
muscle wasting during disuse-induced skeletal muscle atrophy 
(ICU bed rest) and septic shock (6) and is a critical regulator of 
the catabolic response to TNFα (7). NF-κB activation also plays 
a significant signaling role in mechanical ventilation-induced 
diaphragmatic atrophy and contractile dysfunction by increas-
ing transcription of specific atrophy-related genes (8). Hence, 
dysregulated systemic inflammation not only leads to delayed 
resolution of ARDS (5) but also contributes to the development 
of ICUAW.
Another important risk factor for ICUAW is the duration 
of immobilization (9, 10). ICUAW is often associated with res-
piratory muscle weakness (11). The phrenic nerve and diaphragm 
show similar electrophysiological and anatomo-pathological 
abnormalities as the peripheral nerves and muscles, contributing 
to delayed weaning from mechanical ventilation (12, 13). In turn, 
prolonged duration of mechanical ventilation itself can further 
exacerbate the weakness and atrophy of the diaphragm, which is 
often the clinical problem with which these patients present (10, 
14). In addition to prolonged mechanical ventilation, ICUAW is 
also associated with longer ICU stay, increased mortality (3) as 
well as with long-term consequences beyond the hospitalization 
phase, which contribute substantially to the long-term financial 
burden of ARDS survivors on the health-care budget (10, 15, 16).
Although myopathy is a well-known adverse effect of chronic 
glucocorticoid administration (17), it is important to recognize 
that in fact glucocorticoids could potentially downregulate 
detrimental inflammatory pathways involved in ICUAW (1) and 
provide a protective effect if hyperglycemia is controlled (18). 
Experimental ARDS is associated with a significant reduction 
in lung tissue GRα expression (19–21) and increase in GRβ 
mRNA (20) leading to decreased GRα nuclear translocation 
(20). In these experiments, low-dose glucocorticoid treatment, 
contrary to placebo, restored GRα number and function lead-
ing to the resolution of pulmonary inflammation (21, 22). In an 
ex vivo ARDS study, prolonged methylprednisolone treatment, 
contrary to placebo, was associated with upregulation in GRα, 
significant increases in GC–GRα-mediated activities (GRα bind-
ing to NF-κB, GRα binding to GC response element on DNA, 
stimulation of inhibitory protein IκBα, and stimulation of IL-10 
transcription), and significant reductions in NF-κB–κb DNA-
binding and the transcription of TNF-α and IL-1β (23). ARDS 
patients randomized to prolonged methylprednisolone treat-
ment, contrary to placebo, demonstrated a rapid and sustained 
reduction in markers of systemic inflammation (23, 24).
Recent guidelines (25, 26) and reviews (27) have provided an 
incomplete representation of the available evidence on gluco-
corticoid treatment in ARDS by citing imprecise meta-analysis 
(28) or contradictory results among meta-analyses (28, 29). This 
is having significant repercussions for the care of patients with 
ARDS and necessitates a clarification. A meaningful analysis of 
glucocorticoid treatment in ARDS must be founded on present 
understanding of disease pathophysiology and fundamentals 
of pharmacological treatment (5). The beneficial effects of 
glucocorticoid therapy in sepsis and ARDS are affected by four 
critical components of therapy: timing of initiation, dosage, dura-
tion of treatment, and tapering. In the 1980s, based on a faulty 
laboratory model (30), clinical investigations focused on a 1-day 
course of massive doses of methylprednisolone for prevention 
(31) or treatment of ARDS (32). Patients received 120 mg/kg of 
methylprednisolone (31, 32), equivalent to ~1-year of prednisone 
20 mg daily. The prevailing fundamental principle (1950–1980) 
that treatment should be continued until disease resolution 
was omitted from the design of these negative trials (30). The 
findings of these randomized controlled trials (RCTs) halted 
the progress of the field (30). Surprisingly, these obsolete trials 
are often combined with contemporary trials in meta-analyses, 
despite serious inconsistency (28, 33) often producing misleading 
results. Furthermore, these meta-analyses also include selected 
retrospective cohort studies increasing the risk for imprecision 
(34, 35). Over the last 20 years, RCTs have instead investigated 
only low-to-moderate daily dosage (≤1  mg/kg for early ARDS 
and ≤2 mg/kg of methylprednisolone-equivalent for late ARDS) 
for 1–4 weeks; meaningful meta-analyses should focus on these 
RCTs that are relevant today.
Our recent systematic review (36) included trial and patient-
level meta-analyses of eight RCTs (n =  619) investigating pro-
longed low-dose glucocorticoid treatment in ARDS. With high 
certainty, glucocorticoids improved time to extubation (10.1 
fewer days, 95% confidence interval −13.1 to −7.1) and mechani-
cal ventilation-free days at day 28 (5.8 more days, 95% confidence 
interval 3.8–11.5) and with moderate certainty, reduced in-
hospital mortality by 24% (95% confidence interval 2–41%), for 
those randomized before day 14 of ARDS. Importantly, avoiding 
sudden discontinuation of methylprednisolone administration 
after extubation is essential to preserve improvement (36). For 
patients randomized after day 13 of ARDS, the ARDS network 
original report (37) found increased 60-day mortality. However, 
this subgroup (n = 48) had an uncharacteristically low mortality 
(8%) and large differences in baseline characteristics (38). When 
the analysis was adjusted for the imbalances at baseline, the mor-
tality difference lost significance (25.6 vs. 13.2%; p = 0.325) (39). 
The results show that our meta-analysis (36) is also consistent 
with a recent meta-analysis of 13 RCTs (n =  2,005) investigat-
ing low-dose glucocorticoid treatment in community-acquired 
pneumonia (leading cause of ARDS) (40). In addition to a poten-
tial reduction in mortality, glucocorticoid treatment reduced the 
risk of progression to ARDS (relative risk 0.24, 95% confidence 
interval 0.10–0.56) or need for mechanical ventilation (relative 
risk 0.45, 95% confidence interval 0.26–0.79)  –  both moderate 
certainty (40).
Although some reports identified glucocorticoid administra-
tion as a significant risk factor for ICUAW (12, 41) or short- to 
medium-term functional outcome (42, 43), most were unable to 
demonstrate an association between prolonged low-to-moderate 
dose glucocorticoid treatment and electrophysiologically or 
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clinically proven neuromuscular dysfunction (2, 15, 18, 44–48) or 
with any physical outcome at discharge and up to 2 years follow-
ing ARDS (15). Meta-analyses limited to randomized trials inves-
tigating prolonged glucocorticoid treatment in ARDS (29) and 
sepsis (49) have reported a similar rate of ICUAW in the control 
and treated groups. Nevertheless, the ARDS network trial (37) is 
frequently cited for concluding that methylprednisolone is asso-
ciated with a higher rate of neuromuscular weakness. However, 
the actual results of the trial (37) show a similar rate (placebo 
vs. methylprednisolone) of weakness [21 (22%) vs. 26 (30%); 
p =  0.20] and similar 60-day mortality (ARDSnet02 Dataset) 
for those with weakness [3 (14%) vs. 2 (8%)]. In a subsequent 
publication (45), after removal of six patients (five randomized to 
methylprednisolone) with documented weakness at study entry, 
the ARDS network authors confirmed that methylprednisolone 
was not associated with increased incidence of weakness [21 
(24%) vs. 20 (22%)]. Importantly, in the Appendix of the original 
publication (37), Table 7 showed that median duration (days) 
of MV (placebo vs. methylprednisolone) was appreciably lower 
for those randomized to methylprednisolone with [26 (14–38) 
vs. 15 (12–22)] or without weakness [16 (9–30.5) vs. 8.5 (5–21)], 
respectively.
Furthermore, the original ARDS network publication (37) 
placed much attention to a subgroup of methylprednisolone 
patients with weakness reported as a serious adverse event (0 vs. 
9; p <  0.001). An adverse event or suspected adverse reaction 
must be reported to the sponsor within 72 h of identification and 
is considered “serious” (SAE) if, in the view of either the inves-
tigator or sponsor, it results or may result in a serious outcome, 
such as death or prolongation of existing hospitalization (50). 
However, the methylprednisolone patients in question did not 
have increased duration of mechanical ventilation or death in 
comparison to the control group. The methylprednisolone-treated 
patients with SAE related to weakness had a median duration on 
initial mechanical ventilation of 16.5 days (7–28) and only one 
death. The death occurred in a patient with high severity indices 
(APACHE III 99, SOFA score 14) with study drug removed with-
out tapering the day after successful extubation (study day 14) 
that returned to MV 3 days later (without reinstitution of study 
drug in the presence of possible adrenal suppression) and died on 
study day 20 (ARDSnet02 Dataset).
In summary, while ICUAW is an independent predictor 
of prolonged weaning (51) and is associated with increased 
mortality, randomized ARDS trials investigating prolonged 
low-dose glucocorticoid treatment have consistently reported a 
sizable and significant increase in mechanical ventilation-free 
days and reduction in hospital mortality for those randomized 
before day 14 (36). Based on these observations, it is reasonable to 
conclude that glucocorticoid treatment-associated downregula-
tion of systemic inflammation in ARDS does not induce clinically 
relevant neuromuscular dysfunction. Alternatively, any potential 
direct harmful neuromuscular effect of glucocorticoids appears 
outweighed by the overall clinical improvement and reduced 
duration of organ failure, in particular ventilator dependency 
and associated immobilization, which are key risk factors for 
ICUAW.
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